Mankind Pharma shares rise after Kotak upgrades to Buy
Kotak Institutional Equities upgraded Mankind Pharma to “buy” from “add” and raised its target to Rs 3,000. Kotak forecasts EPS growth between FY26 and FY29.
Kotak forecasts a 23 per cent CAGR in earnings per share for Mankind Pharma between financial year 2026 and financial year 2029Shares of Mankind Pharma extended their gains on Tuesday after Kotak Institutional Equities upgraded the pharmaceutical company to ‘buy’ from ‘add’ and raised its price tar…